New Neurotoxin Starts Phase 3 Trials

The injectable neurotoxin drug candidate daxibotulinumtoxinA for injection (RT002, Revance Therapeutics) started phase 3 SAKURA trials in December 2016. The pair of double-blind, placebo-controlled, North American studies are evaluating single injections of daxibotulinumtoxinA for the treatment of glabellar lines in about 600 patients at several study centers, Tina S. Alster, M.D., an investigator for the phase 3 SAKURA trials tells Dermatology Times.
“These pivotal trials follow on the successful BELMONT study announced last year that showed RT002 at the 40U dose produced six-month duration of effect in the treatment of frown lines,” says Dr. Alster, director of the Washington Institute of Dermatologic Laser Surgery and clinical professor of dermatology, Georgetown University Hospital, Washington, DC.
DaxibotulinumtoxinA (RT002) is designed to be the first long-lasting, next-generation injectable neurotoxin, she says.
Read more at Dermatology Times >>